博拓生物：公司将继续坚定在脑机接口领域的战略布局规划

Core Viewpoint - The brain-computer interface (BCI) industry is identified as a long-term investment opportunity in the healthcare sector, with significant strategic importance for the company in the medical device field [1] Summary by Relevant Sections Industry Outlook - The implementation opinions jointly issued by seven departments, including the Ministry of Industry and Information Technology, aim to establish an advanced technology, industry, and standard system for the BCI industry by 2027, and to cultivate 2 to 3 globally influential leading enterprises by 2030 [1] Company Strategy - The company has been researching and exploring the BCI direction since 2023 and strategically invested in Hangzhou Qingshi Yongjun in 2025, successfully entering the invasive BCI treatment field for severe treatment-resistant depression [1] - The recent investment in Haoshi Tianhui further enhances the company's detection and treatment layout for depression and anxiety disorders within the BCI field [1] Future Plans - The company plans to continue its strategic layout in the BCI field by participating deeply through its investment platform, using its own funds for equity participation or acquisitions to accelerate the product industrialization and commercialization processes of invested enterprises [1] - Additionally, the company intends to establish a BCI industry fund, leveraging the strengths and resources of professional investment institutions to expedite its industrial chain layout in the BCI and neuroscience fields [1]